1.Hypoxia change the gene expression of insulin-like growth factors family in rat prefrontal cortex.
Hu-Yue ZU ; Zhuan QU ; Ji-Long REN ; Xue-Qun CHEN ; Ji-Zeng DU
Chinese Journal of Applied Physiology 2014;30(1):30-32
Animals
;
Gene Expression
;
Hypoxia
;
metabolism
;
Prefrontal Cortex
;
metabolism
;
Rats
;
Somatomedins
;
metabolism
3.Clinical efficacy and safety of avastin combined with FOLFOX in the treatment of advanced metastatic colorectal cancer
The Chinese Journal of Clinical Pharmacology 2015;31(22):2208-2210
Objective To evaluate the clinical efficacy and safety of avastin combined with FOLFOX in the treatment of advanced metastatic colorectal cancer.Methods Sixty-four patients with advanced meta-static colorectal cancer patients were divided into treatment group (31 cases) and control group (33 cases).Control group was treated with FOLFOX chemotherapy regimen, oxaliplatin 85 mg·m-2 +leucovorin 200 mg·m-2 +fluorouracil 400 mg·m-2 , once two week, 2 times for a course of treatment.Treatment group was based on the control group, and addition of bevacizumab 10 mg·kg -1 , in the second day after the start of intravenous chemotherapy, at least four times, two times a week to repeat.After two cycles of chemotherapy, the objective response rate and chemotherapy related adverse drug reactions were compared between the two groups.Results The objective response rates were 41.94%and 18.18% in treatment and control group with significant difference (P<0.05).The median survival of the treatment group were 12.6 months was much longer than that 9.1 months in control group ( P <0.05).But the grade Ⅲ-Ⅳchemotherapy related toxicity was not sta-tistical different between the two groups( P>0.05).Conclusion FOL-FOX combined with avastin can significantly improve the clinical efficacy in patients with metastasis colorectal cancer without increasing the risk of developing gradeⅢ-Ⅳadverse drug reactions.
4.Influence of recombined human growth hormone on sIgA and EGF in rats with obstructive jaundice.
Zong-li SUN ; Xue-ting WANG ; Wu-wei LI ; Li-qun REN ; Lei GU ; Xian-li LIU
Chinese Journal of Applied Physiology 2007;23(2):241-244
AIMTo study the effect of the recombined human growth hormone(rhGH) on secretory immunoglobulin A (sIgA), epidermal growth factor (EGF) in rats with obstructive jaundice.
METHODSSixty Wistar rats were randomly divided into four groups, sham-operated (group A), common biliary duct-ligated (group B), biliary duct-ligated plus rhGH-treat for one week (group C), biliary duct-ligated plus rhGH-treat for two weeks (group D), each group had 15 rats. Except group A, the rats of other groups were operated with biliary duct-ligated. Until two weeks after operation, the rats of group A and B were killed. After operation, the rats of group C were treated with rhGH hypodermic injection (0.75 U x kg(-1) x d(-1)) for one week, and then killed. The rats of D group were treated with rhGH hypodermic injection (0.75 U x kg(-1) x d(-1)) for two weeks, and then killed. All procedures were performed aseptically. Total bilirubin (TB), alkaline phosphatase (ALP), prealbumin(PA), insulin-like growth factor (IGF-1), sIgA, EGF were measured.
RESULTSCompared with group A, in group B, C, D, serum level of PA, IGF-1 and sIgA, EGF level of gastric and intestinal juice were lower, but TB, ALP were higher, there were significant difference. Compared with group B, the rats with treatment of rhGH in group C and D had higher sIgA and EGF and lower intestinal bacterial translocation.
CONCLUSIONIn objective jaundice rats, rhGH can protect their hepatic function, intestinal physical-barrier function and immune-barrier function, and reduce intestinal bacterial translocation.
Animals ; Bacterial Translocation ; Epidermal Growth Factor ; metabolism ; Growth Hormone ; pharmacology ; Humans ; Immunoglobulin A, Secretory ; metabolism ; Jaundice, Obstructive ; metabolism ; Rats ; Rats, Wistar ; Recombinant Proteins ; pharmacology
5.Application of flow cytometric immunophenotypic analysis in the diagnosis of malignant lymphoma.
Li-Qun REN ; Li-Yan XUE ; Rui BI ; Jian-Ming LIANG ; Dong-Mei LIN ; Jie MA ; Ning LÜ
Chinese Journal of Hematology 2007;28(10):671-676
OBJECTIVETo explore the value of flow cytometric immunophenotyping (FCI) in the diagnosis and differentiated diagnosis of lymphoma and explain the immunophenotypic features and differences of malignant lymphoma.
METHODSSeventy four fresh samples of suspicious lymphoma were collected from Nov. 2004 to Aug. 2006. Each sample was individually evaluated by FCI. The results were analyzed and compared with the histopathological diagnosis.
RESULTSAmong the 74 cases, the FCI data consisted with the final morphological diagnosis in 61 cases (82.4%). For the diagnosis of B and T non-Hodgkin's lymphoma (NHL), thymoma, carcinoma and benign lesions of lymph node, the concordance between FCI data and morphological diagnosis were 93.5%, 100%, 100%, 100% and 81.3%, respectively.
CONCLUSIONMulti-parameter FCI analysis can provide important information and help for diagnosis of lymphoma. It is an assistant but necessary approach for the diagnosis and differential diagnosis of lymphoma.
Adolescent ; Adult ; Aged ; Child ; Female ; Flow Cytometry ; Humans ; Immunophenotyping ; methods ; Lymphoma ; diagnosis ; immunology ; pathology ; Male ; Middle Aged
6.Efficacy of Prescriptions for Softening Hardness to Dissipate Mass Combined with Levothyroxine Sodium in the Treatment of Postoperative Patients with Thyroid Cancer:A Meta-analysis
Hao-Qun FAN ; Jian-Chun WU ; Cong LIAO ; Xue-Ren AO
Journal of Guangzhou University of Traditional Chinese Medicine 2024;41(3):798-808
Objective To systematically evaluate the clinical efficacy of the prescriptions for softening hardness to dissipate mass combined with Levothyroxine Sodium in the treatment of postoperative thyroid cancer,and to provide evidence-based medical proof for clinical treatment of postoperative thyroid cancer.Methods Computer search was performed in the major domestic and oversea databases for the retrieval of clinical randomized controlled trials(RCTs)of prescriptions for softening hardness to dissipate mass combined with Levothyroxine Sodium for the treatment of postoperative thyroid cancer.After screening the literature according to the inclusion and exclusion criteria,the quality of the included literature was evaluated using the tools for analysis of the bias recommended by Cochrane Reviewer's Handbook and the modified JADAD rating scale,and meta-analysis was performed using RevMan 5.4 software.Results A total of 11 RCTs involving 749 patients were eventually included.The results of meta-analysis showed that compared with Levothyroxine Sodium alone,prescriptions for softening hardness to dissipate mass combined with Levothyroxine Sodium significantly enhanced the efficacy of postoperative patients with thyroid cancer(RR=1.30,95%CI[1.21,1.41],Z = 6.81,P<0.000 01),and improved the thyroid functions parameters of serum thyroid stimulating hormone(TSH)(SMD=-1.75,95%CI[-2.38,-1.13],Z = 5.47,P<0.000 01),thyroglobulin(TG)(SMD=-1.13,95%CI[-1.71,-0.55],Z = 3.81,P = 0.000 1),free triiodothyronine(FT3)(SMD=3.42,95%CI[0.73,6.10],Z = 2.50,P = 0.01),free thyroxine(FT4)(SMD=1.85,95%CI[0.05,3.66],Z = 2.02,P = 0.04),and thyroglobulin antibody(TgAb)(SMD=-0.63,95%CI[-1.11,-0.15],Z = 2.55,P = 0.01),increased Karnofsky Performance Status(KPS)scores(SMD= 2.19,95%CI[1.30,3.08],Z = 4.81,P<0.000 01),shortened the time for the relief of clinical symptoms after thyroid cancer surgery(MD=-4.67,95%CI[-5.38,-3.96],Z = 12.87,P<0.000 01),reduced the diameter of the largest thyroid nodule after thyroid cancer surgery(MD=-2.51,95%CI[-3.13,-1.89],Z = 7.94,P<0.000 01),regulated the immune function indicators of T lymphocyte population CD3+(MD=8.68,95%CI[4.97,12.39],Z = 4.59,P<0.000 01)and CD4+(MD=10.77,95%CI[5.46,16.08],Z = 3.97,P<0.000 1)levels,and reduced the incidence of postoperative complications of thyroid cancer(RR=0.34,95%CI[0.18,0.65],Z = 3.26,P = 0.001).The differences were all statistically significant(P<0.05).Conclusion prescriptions for softening hardness to dissipate mass combined with Levothyroxine Sodium can enhance the efficacy of postoperative patients with thyroid cancer.The combined therapy is superior to Levothyroxine Sodium alone in improving thyroid function indicators,KPS score,time for the relief of clinical symptoms,diameter of the largest thyroid nodule,immune function indicators,and the incidence of postoperative complications.However,due to the small amount of included trials and the fact that the prescriptions for softening hardness to dissipate mass vary in the composition,the conclusions of the analysis need to be confirmed by more high-quality,multi-center,large-sample clinically randomized controlled trials.
7.Effect and its mechanism of FoxO3a activates FasL on renal tubular epithelial cell apoptosis induced by renal ischemia/reperfusion injury
Jian XU ; Yan WANG ; Huai-Xue JI ; Shu-Qun HU ; Hong-Yan DONG ; Ling REN
The Chinese Journal of Clinical Pharmacology 2014;(10):929-931
Objective To explore the role and mechanism of forkhead box proteinO3a activates Fas ligand on renal tubular epithelial cell ( RTC ) apoptosis induced by renal ischemia /reperfusion ( I/R ) . Methods The model by clamping renal pedicles for 45 minutes follow-ing reperfusion was established.The protein expression of forkhead box proteinO3a and Fas ligand were examined by western blotting.Apoptosis of RTC was assessed by TdT -mediated dUTP nick -end Labeling (TUNEL) method and transmission electron microscopic (TEM).Renal function was assessed by biochemical automatic analyzer .Results The protein expression level of forkhead box proteinO 3a and Fas ligand was increased significantly following renal I /R at 1 h.RTC nucleus was shrinking, crushing followed renal I /R, and a significant increase in the number of TUNEL -positive cells following renal I /R was displayed com-pared with the sham group.The level of blood urea nitrogen(BUN) and serum creatinine ( Scr) was increased significantly compared with the sham group (P <0.05,P <0.01).Conclusion FoxO3a could be acti-vated during renal I /R, and then up -regulated FasL protein expression , facilitated renal tubular epithelial cell apoptosis , in turn, aggravated renal I /R injury in rats.
8.Expression and significance of clusterin in normal prostate, benign prostate hyperplasia and prostate cancer.
Li-qun ZHOU ; Xue-zhen YANG ; Li ZENG ; Li-li LIANG ; Xin-yu YANG ; Liang REN ; Lee CHUNG ; Zhi-wen ZHANG ; Yan-qun NA ; Fang-liu GU ; Ying-lu GUO
Chinese Journal of Surgery 2003;41(2):93-95
OBJECTIVETo investigate the expression and significance of Clusterin in normal prostate, benign prostate hyperplasia (BPH) and prostate cancer.
METHODSClusterin expression in samples of 12 normal prostate, 15 BPH, and 56 prostate cancer were studied by immunohistochemical stain.
RESULTSOf 83 cases, 67 are positive or weak positive (81%). The rate of positive or weak positive for normal prostate, BPH and prostate cancer was 17% (2/12), 73% (11/15), and 96% (54/56) respectively. The expression level of Clusterin in prostate cancer was much higher than in normal prostate (t = 8.82, P < 0.01). BPH (t = 7.63, P < 0.01) was related positively with pathological grade (r = 0.649, P < 0.01) and stage (r = 0.609, P < 0.01) of prostate cancer.
CONCLUSIONClusterin may play an important role in the biological characteristics of prostate cancer by the anti-apoptosis pathway.
Apoptosis ; Clusterin ; metabolism ; physiology ; Female ; Humans ; Immunohistochemistry ; Male ; Prostate ; metabolism ; Prostatic Hyperplasia ; metabolism ; Prostatic Neoplasms ; metabolism ; pathology ; physiopathology
9.Efficacy and safety of Saw Palmetto Extract Capsules in the treatment of benign prostatic hyperplasia.
Xiao-bing JU ; Xiao-jian GU ; Zheng-yu ZHANG ; Zhong-qing WEI ; Zhuo-qun XU ; Hui-dong MIAO ; Wei-min ZHOU ; Ren-fang XU ; Bin CHENG ; Jian-guo MA ; Tian-li NIU ; Ping QU ; Bo-xin XUE ; Wei ZHANG
National Journal of Andrology 2015;21(12):1098-1101
OBJECTIVETo assess the efficacy and safety of Saw Palmetto Extract Capsules in the treatment of benign prostatic hyperplasia (BPH).
METHODSWe conducted a multi-centered open clinical study on 165 BPH patients treated with Saw Palmetto Extract Capsules at a dose of 160 mg qd for 12 weeks. At the baseline and after 6 and 12 weeks of medication, we compared the International Prostate Symptom Scores (IPSS), prostate volume, postvoid residual urine volume, urinary flow rate, quality of life scores (QOL), and adverse events between the two groups of patients.
RESULTSCompared with the baseline, both IPSS and QOL were improved after 6 weeks of medication, and at 12 weeks, significant improvement was found in IPSS, QOL, urinary flow rate, and postvoid residual urine. Mild stomachache occurred in 1 case, which necessitated no treatment.
CONCLUSIONSaw Palmetto Extract Capsules were safe and effective for the treatment of BPH.
Capsules ; Humans ; Male ; Plant Extracts ; adverse effects ; therapeutic use ; Prostatic Hyperplasia ; drug therapy ; Quality of Life
10.Expression of annexin I in different histological types of carcinomas.
Li-Yan XUE ; Liang-Hong TENG ; Shuang-Mei ZOU ; Li-Qun REN ; Shan ZHENG ; Wei LUO ; Rui BI ; Ning LÜ
Chinese Journal of Oncology 2007;29(6):444-448
OBJECTIVETo investigate the expression of annexin I in esophageal squamous cell carcinoma (SCC) and carcinomas of other histological types in order to analyze the correlation between the expression of annexin I and carcinogenesis.
METHODSFirst, a set of tissue microarray was established, which consisted of SCC from the esophagus (208 cases), lung, larynx, cervix, and external genital organs; adenocarcinomas from the lung, stomach, colon and rectum, liver, pancreas, breast, thyroid and kidney with 30 cases in each group, meanwhile, the corresponding normal tissue was also obtained for control. Immunohistochemistry was used to detect the expression of annexin I in different types of carcinomas and the corresponding normal controls from different organs. The correlation between the expression of annexin I and the clinicopathological feature was analyzed and compared, which included age, gender, differentiation grade and lymph node metastasis.
RESULTSIt was found that the expression of annexin I was decreased in esophageal SCC, when compared with normal esophageal squamous epithelia (P < 0.001), the similarity was also found in SCC of the lung, larynx and cervix. However, though negative in normal epidermis, annexin I expression was detected in some cases with SCC from external genital organs. Annexin I was found to be overexpressed in adenocarcinomas of the lung, stomach, colon and rectum, liver, pancreas, breast, thyroid and kidney, particularly very strong expression of annexin I was seen in lung adenocarcinoma, uterine endometrioid adenocarcinoma and ovarian serous adenocarcinoma. Interestingly, it was found to be positive in all thyroid papillary carcinomas, but negative in all normal thyroid glands. However, annexin I expression was found to be negative in all hepatocellular carcinoma and normal hepatocytes; and it was only detected in myoepithelium of normal breast tissue, but not in ductal luminal cells, and rarely in infiltrating ductal adenocarcinoma. In SCC, annexin I expression was stronger in well differentiated ones than that in the poorly differentiated ones. However, contrasting with SCC, in the adenocarcinomas from different organs, annexin I expression was much stronger in poorly differentiated ones than that in the well differentiate ones, especially in the adenocarcinomas from stomach, colon and rectum, pancreas, ovarian and kidney.
CONCLUSIONAnnexin I expression is quite different among different types of carcinomas, and is correlated with histopathological type and differentiation grade. Further study is needed to investigate its role in the carcinogenesis.
Adenocarcinoma ; metabolism ; pathology ; Annexin A1 ; metabolism ; Carcinoma, Endometrioid ; metabolism ; pathology ; Carcinoma, Squamous Cell ; metabolism ; pathology ; Cell Differentiation ; Endometrial Neoplasms ; metabolism ; pathology ; Epithelium ; metabolism ; Esophageal Neoplasms ; metabolism ; pathology ; Esophagus ; metabolism ; Female ; Humans ; Immunohistochemistry ; Lung Neoplasms ; metabolism ; pathology ; Stomach Neoplasms ; metabolism ; pathology